Anderson brings over 30 years of experience in research, biostatistics, and leadership to the Max board. She currently provides strategic support as Clinical Biometrics Leader at the Gates Medical Research Institute for the clinical development of therapeutics and vaccines that aim to reduce the burden of tuberculosis and malaria in low- and middle-income countries. Recently published articles that she has co-authored include “Discovery and development of a more selective oxazolidinone for the treatment of tuberculosis: MK-7762 (TBD09)” (Nature Medicine, 2026) and “Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial” (The Lancet Infectious Diseases, 2026). Prior to joining Gates MRI, Anderson was Chief Scientific Officer at Statistics Collaborative – WCG Clinical, a consulting firm based in Washington, DC. And during her 19-year tenure at Bristol-Myers Squibb, she led the statistical strategy and execution for multiple immuno-oncology checkpoint inhibitors.